Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1998-12-15
2000-08-01
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514529, 514530, 514534, 514543, 560 56, 560 60, 560 62, 560118, C07C 69608, C07C 69616, A61K 31215, A61K 31216
Patent
active
060967838
ABSTRACT:
Cyclobutane analogs of PGF.sub.2.alpha., PGD.sub.2, and PGE.sub.2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.
REFERENCES:
patent: 3772350 (1973-11-01), Pike et al.
patent: 4599353 (1986-07-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5093329 (1992-03-01), Woodward
patent: 5321128 (1994-06-01), Stjernschantz et al.
Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology, 4(11):44-50 (1993).
Depres et al., Synthesis of Ring Modified Prostaglandins, Tetrahedron, 37(3): 621-628 (1981).
Flach, Eliason, Topical Prostaglandin E.sub.2 Effects on Normal Human Intraocular Pressure Journal of Ocular Pharmacology, 4(1):13-17 (1988).
Giuffre, The Effects of Prostaglandin F.sub.2.alpha. the Human Eye, Graefe's Arch Clin Exp Ophthalmol, 222:139-141 (1985).
Greene et al., Total Synthesis of 11-Nor Prostaglandins, Tetrahedron Letters, 41:3755-3758 (1976).
Guzman, et al., Synthesis of Cyclobutano Prostaglandins, Chemistry and Industry, 20:884-885 (Oct. 1975).
Ichikawa, Sugimoto, Negishi, Molecular aspects of the structures and functions of the prostaglandin E receptors, J. Lipid Mediators Cell Signalling, 14:83-87 (1996).
Kerstetter et al., Prostaglandin F.sub.2.alpha. -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow, American Journal of Ophthalmology 105:30-34 (1988).
Nakajima et al. Effects of Prostaglandin D.sub.2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, 229:411-413 (1991).
Reuschling et al., Synthese von Cyclobutanprostaglandinen, Tetrahedron Letters, 1:17-18 (1977).
Thierauch et al., Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, 12:1-5 (1994).
Waterbury, et al., EP.sub.3 but not EP.sub.2 FP or TP Prostanoid-Receptor Stimulation May Reduce Intraocular Pressure, Investigative Ophthalmology and Visual Science, 31(12):2560-2567 (Dec. 1990).
Woodward et al., Prostaglandin F.sub.2.alpha. effects on intraocular pressure negatively correlate with FP-Receptor Stimulation Investigative Ophthal & Visual Sci 30(8):1838-1842 (Aug. 1989).
Woodward, et al., Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies, Journal of Lipid Mediators, 6:545-553 (1993).
Woodward, et al., Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP2 Receptor Journal of Ocular Pharmacology and Therapeutics,11(3):447-454 (1995).
Alcon Laboratories Inc.
Copeland Barry L.
Gerstl Robert
LandOfFree
Cyclobutane prostaglandin analogues as ocular hypotensive agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclobutane prostaglandin analogues as ocular hypotensive agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclobutane prostaglandin analogues as ocular hypotensive agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664525